SYRE EBITDA | SPYRE THERAPEUTICS, INC.

SPYRE THERAPEUTICS, INC. (SYRE) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$41.64M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$45.64M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$56.89M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$41.94M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2014-12-31 to 2025-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$41.64M	(m)	(m)	(m)	(m)	-$69.88M*	(m)	(m)	(m)	$0.00
2026-03-31	Reported	(m)	-$45.64M	(m)	(m)	(m)	(m)	-$57.37M	(m)	(m)	(m)	$0.00
2025-09-30	Reported	(m)	-$56.89M	(m)	(m)	(m)	(m)	-$37.12M*	(m)	(m)	(m)	$0.00
2025-06-30	Reported	(m)	-$41.94M	(m)	(m)	(m)	(m)	-$46.56M*	(m)	(m)	(m)	$0.00
2025-03-31	Reported	(m)	-$53.57M	(m)	(m)	(m)	(m)	-$40.99M	(m)	(m)	(m)	-$15.00K
2024-12-31	Reported	-$61.25M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$55.39M*	-$55.39M	$0.00*	$0.00	(m)	(m)	-$29.42M*	(m)	(m)	(m)	$18.00K
2024-06-30	Reported	-$44.15M*	-$44.15M	$0.00*	$0.00	(m)	(m)	-$62.25M*	(m)	(m)	(m)	$0.00
2024-03-31	Reported	-$47.77M	(m)	(m)	(m)	(m)	(m)	-$28.54M	(m)	(m)	(m)	$32.00K
2023-12-31	Reported	-$45.91M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$18.34M*	-$18.34M	$0.00*	$0.00	(m)	(m)	-$34.60M*	(m)	(m)	(m)	$3.00K
2023-06-30	Reported	-$158.89M*	-$159.25M	$360.00K*	$688.00K	-23093.90%*	(m)	-$16.64M*	(m)	(m)	(m)	$7.00K
2023-03-31	Reported	-$18.42M	(m)	(m)	(m)	-9304.04%	(m)	-$17.63M	(m)	$13.78M	(m)	-$36.00K
2022-12-31	Reported	-$18.78M	(m)	(m)	(m)	-11176.79%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$18.35M*	-$18.75M	$401.00K*	$174.00K	-10548.28%*	$1.00K*	-$15.07M*	(m)	$11.98M	(m)	-$209.00K
2022-06-30	Reported	-$22.05M*	-$22.42M	$378.00K*	$625.00K	-3527.20%*	$0.00*	-$20.67M*	(m)	$15.37M	(m)	$9.00K
2022-03-31	Reported	-$24.04M	(m)	(m)	(m)	-1764.90%	$37.00K	-$26.26M	(m)	$16.98M	(m)	$0.00
2021-12-31	Reported	-$20.03M	(m)	(m)	(m)	-549.70%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$19.88M*	-$20.29M	$412.00K*	$1.40M	-1421.09%*	$93.00K*	-$17.00M*	(m)	$14.85M	(m)	$26.00K
2021-06-30	Reported	-$6.31M*	-$6.71M	$398.00K*	$13.70M	-46.05%*	$30.00K*	$2.08M*	(m)	$13.58M	(m)	$92.00K
2021-03-31	Reported	-$17.85M	(m)	(m)	(m)	(m)	$450.00K	-$19.53M	(m)	$11.86M	(m)	(m)
2020-12-31	Reported	-$22.41M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$17.87M*	-$18.12M	$251.00K*	(m)	(m)	$566.00K*	-$17.54M*	(m)	$12.45M	(m)	(m)
2020-06-30	Reported	-$21.34M*	-$21.56M	$222.00K*	(m)	(m)	$1.32M*	-$19.41M*	(m)	$16.87M	(m)	(m)
2020-03-31	Reported	-$18.87M	(m)	(m)	(m)	(m)	$1.39M	-$21.69M	(m)	$14.56M	(m)	(m)
2019-12-31	Reported	-$21.8M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$22.04M*	-$22.15M	$105.00K*	$0.00*	(m)	$143.00K*	-$17.21M*	(m)	$17.84M	(m)	(m)
2019-06-30	Reported	-$18.52M*	-$18.62M	$107.00K*	$0.00*	(m)	$57.00K*	-$16.38M*	(m)	$14.81M	(m)	(m)
2019-03-31	Reported	-$17.56M	(m)	(m)	(m)	(m)	$118.00K	-$15.81M	(m)	$14.39M	(m)	(m)
2018-12-31	Reported	-$15.23M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$12.17M*	-$12.24M	$76.00K*	$0.00	(m)	$101.00K*	-$8.50M*	(m)	$8.93M	(m)	(m)
2018-06-30	Reported	-$9.60M*	-$9.67M	$75.00K*	$2.38M	-403.49%*	$35.00K*	-$9.04M*	(m)	$9.12M	(m)	(m)
2018-03-31	Reported	-$8.18M	(m)	(m)	(m)	-541.39%	$83.00K	-$7.45M	(m)	$6.87M	(m)	(m)
2017-12-31	Reported	-$6.56M	(m)	(m)	(m)	-442.65%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$7.93M*	-$8.00M	$69.00K*	$1.26M	-628.79%*	$111.00K*	(m)	(m)	$6.24M	(m)	(m)
2017-06-30	Reported	-$6.66M*	-$6.72M	$62.00K*	$1.48M	-450.17%*	$46.00K*	(m)	(m)	$5.83M	(m)	(m)
2017-03-31	Reported	-$6.28M	(m)	(m)	(m)	(m)	$271.00K	(m)	(m)	$4.95M	(m)	(m)
2016-12-31	Reported	-$5.51M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$6.27M*	-$6.30M	$34.00K*	(m)	(m)	$0.00*	(m)	(m)	$5.38M	(m)	(m)
2016-06-30	Reported	-$5.46M*	-$5.50M	$33.00K*	(m)	(m)	$89.00K*	(m)	(m)	$4.42M	(m)	(m)
2016-03-31	Reported	-$4.54M	(m)	(m)	(m)	(m)	$2.00K	(m)	(m)	$3.60M	(m)	(m)
2015-12-31	Reported	-$3.97M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	-$3.39M*	-$3.42M	$25.00K*	(m)	(m)	$134.00K*	(m)	(m)	$3.13M	(m)	(m)
2015-06-30	Reported	-$1.41M*	-$1.43M	$18.00K*	(m)	(m)	$24.00K*	(m)	(m)	$2.74M	(m)	(m)
2015-03-31	Reported	-$2.45M	(m)	(m)	(m)	(m)	$10.00K	(m)	(m)	$1.62M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$209.56M	(m)	(m)	(m)	(m)	(m)	-$169.25M	(m)	(m)	(m)	-$15.00K
2024-12-31	Reported	-$208.57M	(m)	(m)	(m)	(m)	$0.00	-$157.41M	(m)	(m)	(m)	$51.00K
2023-12-31	Reported	-$241.56M	(m)	(m)	(m)	-27264.00%	$0.00	-$99.91M	(m)	(m)	(m)	-$26.00K
2022-12-31	Reported	-$83.21M	(m)	(m)	(m)	-3572.95%	$38.00K	-$80.14M	(m)	$58.58M	(m)	-$136.00K
2021-12-31	Reported	-$64.07M	(m)	(m)	(m)	-341.92%	$573.00K	-$53.72M	(m)	$57.07M	(m)	$141.00K
2021-09-30	Rolling	(m)	-$67.98M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	-$65.81M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$80.67M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$80.49M	(m)	(m)	(m)	(m)	$4.28M	-$75.78M	(m)	$59.64M	(m)	$0.00
2020-12-31	Rolling	(m)	-$81.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$80.61M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$84.64M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$81.70M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$79.92M	(m)	(m)	(m)	(m)	$1.49M	-$65.69M	(m)	$64.60M	(m)	$0.00
2019-12-31	Rolling	(m)	-$80.33M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$73.73M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$63.83M*	(m)	$0.00*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$54.88M*	(m)	$2.38M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$45.17M	(m)	(m)	(m)	-1161.78%	$422.00K	-$32.19M	(m)	$36.72M	(m)	$0.00
2018-12-31	Rolling	(m)	-$45.46M*	(m)	$3.89M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$36.78M*	(m)	$5.37M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$32.54M*	(m)	$6.63M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$29.59M*	(m)	$5.73M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$27.43M	(m)	(m)	(m)	-526.94%	$619.00K	-$24.61M	(m)	$22.82M	(m)	$0.00
2017-12-31	Rolling	(m)	-$27.68M*	(m)	$5.21M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$26.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$24.89M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$23.67M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$21.77M	(m)	(m)	(m)	-470.48%	$212.00K	-$18.84M	(m)	$18.14M	(m)	$0.00
2016-12-31	Rolling	(m)	-$21.91M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$20.36M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$17.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$13.41M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$11.23M	(m)	(m)	(m)	(m)	$208.00K	(m)	(m)	$11.45M	(m)	$0.00
2015-12-31	Rolling	(m)	-$11.31M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	-$8.89M	(m)	(m)	(m)	(m)	$181.00K	(m)	(m)	$6.83M	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Structure Therapeutics Inc. (GPCR)	United States	$7.710B	-53.41
Praxis Precision Medicines, Inc. (PRAX)	United States	$7.884B	-27.60
IONIS PHARMACEUTICALS INC (IONS)	United States	$7.277B	-23.25
Alkermes plc. (ALKS)		$6.844B	132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)	United States	$6.771B	-37.20
TG THERAPEUTICS, INC. (TGTX)	United States	$8.805B	19.05
Protagonist Therapeutics, Inc (PTGX)	United States	$8.883B	95.52
Liquidia Corp (LQDA)	United States	$6.347B	51.23
Amneal Pharmaceuticals, Inc. (AMRX)		$6.326B	25.62
CYTOKINETICS INC (CYTK)	United States	$9.130B	-11.86